Effectiveness of Systemic Immune-Inflammatory Index in Predicting Bone Metastasis in Newly Diagnosed Prostate Cancer Patients

Rilian Song; Gaomeng Wei; Baode Lu; Dingxi Jian; Zilu Zhang

doi:10.54097/b92jdk60

Authors

Rilian Song
Gaomeng Wei
Baode Lu
Dingxi Jian
Zilu Zhang

DOI:

https://doi.org/10.54097/b92jdk60

Keywords:

Prostate Cancer, Systemic Immune Inflammation Index, Bone Metastasis

Abstract

Objective To explore the effectiveness of systemic immune inflammation index (Systemic immune-inflammation index, SII) in predicting bone metastasis in patients with newly diagnosed prostate cancer (Prostatic cancer, PCa). Methods The retrospective analysis of 200 cases of prostate cancer from January 2020 to June 2023 and 70 cases of bone metastasis compared the expression difference of SII between the two groups and analyzed the clinical diagnostic value of SII in prostate cancer bone metastasis. The resulting SII in the bone metastasis group was 500.63(351.24-696.57) 109/ L, the SII in the no-bone metastasis group was 350.12(258.41-529.40) 109/ L, statistically significant, P <0.05. The ROC curve analysis revealed that its sensitivity was 68.63% and its specificity was 60.95%. Conclusion System immune inflammation index (SII) has certain application value for bone metastasis in patients with newly diagnosed prostate cancer (PCa), and high level of SII indicates poor prognosis, which is worth further clinical study.

Downloads

Download data is not yet available.

References

[1] Liang Anshi, Xie Caiye. Predictive value of systemic immune inflammatory nutrition index in elderly patients undergoing laparoscopic radical prostate cancer [J]. Chinese Sex Science, 2023,32 (11): 30-34.

[2] Shi Jiahao, Chen Chunyang, Wang Zhirong, et al. Prediction of systemic immune inflammation index versus monocyte-lymphocyte count for biochemical recurrence after prostate cancer surgery [J]. International Journal of Urology, 2023,43 (6): 1010-1015.

[3] Man Yanan, Chen Yanfang. Impact of systemic immune inflammation index and serum albumin on patients with castration-resistant prostate cancer treated with first-line docetaxel [J]. Chinese Journal of Metastatic Oncology, 2022,05 (3): 209-214.

[4] Gao Jun, Song Weijie, Liu Xianghu, et al. Predictive value of systemic immune inflammation index for bone metastases in first diagnosed prostate cancer patients [J]. Chinese Journal of Urology, 2021,42 (10): 752-757.

[5] Pan Zhengbo, Cheng Weisong, Cai Hairong, et al. Correlation between preoperative systemic immune inflammation index and prognosis of patients after high-risk / extremely high-risk prostate cancer [J]. Chinese Modern Doctor, 2020,58 (13): 49-52,56.

[6] Liu Hongbo, Xiao Hongxia, Tian Yuting. Diagnostic value of combining PSA and NTx and D-D index for bone metastasis in prostate cancer [J]. Health Engineering of China, 2022,21 (6): 1035-1037,1040.

[7] Wang Yongxiang, Zhao Xinghua, Xu Changbao, et al. Risk factor analysis and prediction model establishment of bone metastasis in first diagnosed prostate cancer [J]. Medical Information, 2023,36 (11): 16-20.

[8] Zhang Zhiyu, Song Zhen, Zhou Qi, et al. Predictive value of preoperative inflammatory markers for clinically meaningful prostate cancer in patients with PI-RADS score 3 [J]. Journal of Dalian Medical University, 2023,45 (3): 198-203,209.

[9] RUANE‐MCATEER EIMEAR, PORTER SAM, OSULLIVAN JOE, et al. Investigating the psychological impact of active surveillance or active treatment in newly diagnosed favorable‐risk prostate cancer patients: A 9‐month longitudinal study[J]. Psycho-Oncology: Journal of the Psychological Social and Behavioral Dimensions of Cancer,2019,28(8):1743-1752.

[10] IARROBINO, NICK A, GILL, et al. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial[J]. American Journal of Clinical Oncology: Cancer Clinical Trials,2019,42(11):856-861.